- Home
- QFIN vs VKTX Comparison
QFIN vs VKTX Comparison
Compare QFIN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- VKTX
- Stock Information
- Founded
- QFIN 2016
- VKTX 2012
- Country
- QFIN China
- VKTX United States
- Employees
- QFIN N/A
- VKTX N/A
- Industry
- QFIN Finance: Consumer Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- VKTX Health Care
- Exchange
- QFIN Nasdaq
- VKTX Nasdaq
- Market Cap
- QFIN 3.4B
- VKTX 3.8B
- IPO Year
- QFIN 2018
- VKTX 2015
- Fundamental
- Price
- QFIN $20.80
- VKTX $37.46
- Analyst Decision
- QFIN Strong Buy
- VKTX Strong Buy
- Analyst Count
- QFIN 2
- VKTX 14
- Target Price
- QFIN $45.10
- VKTX $87.00
- AVG Volume (30 Days)
- QFIN 1.9M
- VKTX 4.8M
- Earning Date
- QFIN 11-18-2025
- VKTX 10-22-2025
- Dividend Yield
- QFIN 7.21%
- VKTX N/A
- EPS Growth
- QFIN 68.82
- VKTX N/A
- EPS
- QFIN 7.06
- VKTX N/A
- Revenue
- QFIN $2,618,582,596.00
- VKTX N/A
- Revenue This Year
- QFIN $17.10
- VKTX N/A
- Revenue Next Year
- QFIN $6.28
- VKTX N/A
- P/E Ratio
- QFIN $2.99
- VKTX N/A
- Revenue Growth
- QFIN 9.77
- VKTX N/A
- 52 Week Low
- QFIN $20.45
- VKTX $18.92
- 52 Week High
- QFIN $48.94
- VKTX $79.10
- Technical
- Relative Strength Index (RSI)
- QFIN 23.89
- VKTX 65.54
- Support Level
- QFIN $20.45
- VKTX $33.00
- Resistance Level
- QFIN $27.59
- VKTX $36.11
- Average True Range (ATR)
- QFIN 1.13
- VKTX 1.92
- MACD
- QFIN -0.50
- VKTX 0.20
- Stochastic Oscillator
- QFIN 4.65
- VKTX 95.79
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.